• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    C

    Coalition for Research in Women's Health

    29论文总数
    2,777引用总数

    论文量&引用量时间轴

    机构学者

    论文(29)

    年份
    起
    –
    止
    排序
    1Post-Secondary Student Mental Health and Well-being: a Systems and Intersectionality-Informed Approach
    Nazilla Khanlou
    2019International Journal of Mental Health and Addiction(2019)引用:6
    引用
    AI阅读
    加入学术空间
    2HER1 Signaling Mediates Extravillous Trophoblast Differentiation in Humans1
    J. K. Wright,C. E. Dunk,H. Amsalem, C. Maxwel,S. Keating,S. J. Lye

    This study examines the role of HER1 signaling in the differentiation of proliferative extravillous trophoblast (EVT) into invasive EVT. Using the JAR choriocarcinoma cell line and placental villous explants as experimental models and immunohistochemical assessment of protein markers of EVT differentiation (downregulation of HER1 and Cx40 and upregulation of HER2 and alpha1 integrin), we show that the ability of decidual conditioned medium (DCM) to induce HER1/2 switching was abrogated in the presence of the HER1 antagonist, AG1478. Similarly, epidermal growth factor (EGF) treatment resulted in the downregulation of HER1 and an upregulation of HER2 expression, whereas co-incubation of EGF with AG1478 inhibited this response. However, EGF did not downregulate Cx40 or induce migration of EVT. In contrast, heparin-binding epidermal-like growth factor (HBEGF) stimulated dose-dependent JAR cell migration, which was inhibited by both AG1478 and AG825 (HER2 antagonist). Western blot analysis of HER1 activation demonstrated that HBEGF-mediated phosphorylation of the HER1 Tyr992 and Tyr1068 sites, while EGF activated the Tyr1045 site. Moreover, HBEGF induced a stronger and more sustained activation of both the mitogen-activated protein kinase and phosphoinositol 3 kinase (PIK3) signaling pathways. Migration assays using a panel of signaling pathway inhibitors demonstrated that the HBEGF-mediated migration was dependent on the PIK3 pathway. These results demonstrate that HBEGF-mediated HER1 signaling through PIK3 is an important component of EVT invasion.

    2010Biology of Reproduction(2010)引用:24
    引用
    AI阅读
    加入学术空间
    3Treading Water: the No-Growth Investment in Health Services Research.
    Emily J Holubowich,Joseph R Antos

    There is a "perfect storm" brewing in the American healthcare system. Healthcare spending has grown faster than our economy for many years and is projected to double in as little as 10 years. In spite of what we spend on healthcare, research tells us that we only receive appropriate care half the time. We are simply not getting what we are paying for. Health services research provides the data and the evidence needed to make better decisions, design healthcare benefits, and develop effective policies to optimize healthcare financing, facilitate access to healthcare services, and improve healthcare outcomes. Despite what we know and what we can learn from health services research, federal funding for this important field continues to erode. This article provides a primer on the federal budget process and summarizes findings from the Federal Funding for Health Services Research 2007.

    2008PubMed(2008)引用:23
    引用
    AI阅读
    加入学术空间
    4CHEK2-positive Breast Cancers in Young Polish Women.
    Cezary Cybulski,Bohdan Gorski,Tomasz Huzarski,Tomasz Byrski,Jacek Gronwald,Tadeusz Debniak,Dominika Wokolorczyk,Anna Jakubowska,Elzbieta Kowalska,Oleg Oszurek,Steven A. Narod,Jan Lubinski

    PURPOSE:To investigate the contribution of CHEK2 mutations to early-onset breast cancer in Poland and to establish the characteristic features of these cancers.EXPERIMENTAL DESIGN:We studied 3,228 women diagnosed with breast cancer under the age of 51 years and 5,496 population controls. CHEK2 mutations were detected by RFLP-PCR or allele-specific oligonucleotide-PCR assays. Clinical and pathologic features of CHEK2-positive cases and CHEK2-negative cases were compared.RESULTS:A truncating CHEK2 mutation (1100delC or IVS2+1G>A) was seen in 47 of 3,228 cases and in 34 of 5,496 controls (odds ratio, 2.4; P = 0.0001). The CHEK2 I157T missense mutation was present in 207 of 3,228 cases, compared with 264 of 5,496 controls (odds ratio, 1.4; P = 0.002). Breast cancers in women with a CHEK2 mutation were more commonly of lobular histology (21.5% versus 15.8%; P = 0.05), of size >2 cm (54.8% versus 43.5%; P = 0.01), or of multicentric origin (28.7% versus 19.5%; P = 0.01) than were cancers from women without a CHEK2 mutation. Bilateral cancers were equally common in both subgroups.CONCLUSION:Three founder alleles in CHEK2 contribute to early-onset breast cancer in Poland. Breast tumors which arise in carriers of CHEK2 mutations seem to be similar to those of breast cancers in the population at large.

    2006Clinical Cancer Research(2006)引用:41
    引用
    AI阅读
    加入学术空间
    5Tamoxifen and Contralateral Breast Cancer in BRCA1 and BRCA2 Carriers: an Update
    J Gronwald,N Tung,WD Foulkes,K Offit,R Gershoni, M Daly,C Kim-Sing,H Olsson,P Ainsworth,A Eisen,H Saal,E Friedman,

    Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of ∼80%, and following the first diagnosis the10‐year risk of contralateral breast cancer is ∼30%. It has been shown that both tamoxifen and oophorectomy prevent contralateral breast cancer, but it is not clear whether there is a benefit in giving tamoxifen to women who have previously undergone an oophorectomy. Furthermore, the relative degree of protection in BRCA1 and BRCA2 carriers has not been well evaluated. We studied 285 women with bilateral breast cancer and a BRCA1 or BRCA2 mutation, and 751 control women with unilateral breast cancer and a BRCA1 or BRCA2 mutation in a matched case‐control study. Control women were of similar age and had a similar age of diagnosis of breast cancer and had been followed for as long as the case for a second primary breast cancer. The history of tamoxifen use for treating the first breast cancer was compared between bilateral and unilateral cases. The multivariate odds ratio for contralateral breast cancer associated with tamoxifen use was 0.50 for carriers of BRCA1 mutations (95% CI, 0.30–0.85) and was 0.42 for carriers of BRCA2 mutations (95% CI, 0.17–1.02). The protective effect of tamoxifen was not seen among women who had undergone an oophorectomy (OR = 0.83; 95%CI, 0.24–2.89) but this subgroup was small. In contrast, a strong protective effect of tamoxifen was apparent among women who were premenopausal or who had undergone natural menopause (OR = 0.44; 95% CI, 0.27–0.65). © 2005 Wiley‐Liss, Inc.

    2005International Journal of Cancer(2005)引用:332
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 29 篇论文

    合作机构(51)

    多伦多大学合作论文 10
    克瑞顿大学合作论文 6
    芝加哥大学合作论文 4
    不列颠哥伦比亚癌症机构合作论文 4
    宾夕法尼亚大学合作论文 4
    舍巴医疗中心合作论文 3
    McGill University合作论文 3
    乔治敦大学合作论文 3
    拉姆巴姆医疗保健园区合作论文 3
    International Hereditary Cancer Center合作论文 3

    机构统计